CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)
The objective of this program is to allow treating physicians to supply/continue to supply
Certolizumab Pegol (CIMZIA®, CZP) to adults suffering from Crohn's Disease (CD), and who are
considered not suitable for treatment, intolerant, have medical contraindications or had
insufficient response with an authorized conventional therapy, including other authorized
biologics.